Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

BDRX stock hub

Biodexa Pharmaceuticals Plc has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BDRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

BDRX

In the news

Latest news · BDRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-64.7

P25 -105.6P50 -46.5P75 -3.1

ROIC-294.9

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BDRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

175

Groups with data

Currency

GBP

Showing 175 of 175 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001643918
Company name	Biodexa Pharmaceuticals Plc
Country	United Kingdom
Country code	US
Cusip	59564R872
Employees	11
Employees Change	-2%
Employees Change Percent	-15.38
Enterprise value	$-8.6M
Exchange	NASDAQ
Financial currency	GBP
First seen	2026-05-09
Industry	Biotechnology
Isin	US59564R8723
Last refreshed	2026-05-10
Market cap	$2.8M
Market cap category	Nano-Cap
Price	$4.25
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	BDRX
Website	https://www.biodexapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-311.84%
FCF yield	-276.73%
P/B ratio	0.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-5.3M
Net Income	$-8.6M
Net Income Growth Years	0%
Profit Per Employee	$-781,109
ROA	-32.79
Roa5y	-47.92
ROCE	-71.74
ROE	-64.72
Roe5y	-101.9
ROIC	-294.9

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-84.36%
Cagr1y	-93.85%
Cagr3y	-94.17%
Cagr5y	-93.69%
EPS Growth Years	4
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$24.5M
Cash	$11.5M
Current Assets	$17M
Current Liabilities	$8.4M
Debt	$82,100
Debt Equity	$0.01
Equity	$15.3M
Interest Coverage	-37.75
Liabilities	$9.1M
Long Term Assets	$7.5M
Long Term Liabilities	$761,424
Net Cash	$11.4M
Net Cash By Market Cap	$414
Net Cash Growth	53.86%
Net Debt Equity	$-0.74
Tangible Book Value	$7.8M
Tangible Book Value Per Share	$17.17
WACC	18.89

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.03
Net Working Capital	$-2.9M
Quick ratio	1.43
Working Capital	$8.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-100%
1Y total return	-93.84%
200-day SMA	19.72
3Y total return	-99.98%
50-day SMA	3.82
50-day SMA vs 200-day SMA	50under200
5Y total return	-100%
All Time High	734,000,000
All Time High Change	-100%
All Time High Date	2015-12-08
All Time Low	2.86
All Time Low Change	48.6%
All Time Low Date	2026-04-13
ATR	0.51
Beta	1.16
Beta1y	2.01
Beta2y	1.51
Ch YTD	-62.56
High	4.75
High52	96.5
High52 Date	2025-05-22
High52ch	-95.6%
Low	4.2
Low52	2.86
Low52 Date	2026-04-13
Low52ch	48.6%
Ma50ch	11.29%
Premarket Change Percent	-5.14
Premarket Price	$4.61
Premarket Volume	8,248
Price vs 200-day SMA	-78.44%
RSI	55.32
RSI Monthly	26.91
RSI Weekly	25.88
Sharpe ratio	-0.77x
Sortino ratio	-1.26
Tr YTD	-62.56
Tr1m	26.87%
Tr1w	40.26%
Tr3m	-31.45%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-11.6M

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	550,717%
Float Percent	84.95%
Net Borrowing	-948,857.1
Shares Insiders	0.43%
Shares Institutions	1.34%
Shares Out	648,313
Shares Qo Q	234.24%
Short Float	7.43%
Short Ratio	0.03
Short Shares	6.31

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-7.9M
Average Volume	989,061.35x
Bv Per Share	33.99
CAPEX	$-2,692
Ch10y	-100
Ch1m	26.87
Ch1w	40.26
Ch1y	-93.84
Ch3m	-31.45
Ch3y	-99.98
Ch5y	-100
Ch6m	-84.26
Change	-12.55%
Change From Open	-9.38
Close	4.86
Days Gap	-3.5
Depreciation Amortization	70,891.6
Dollar Volume	343,689
Earnings Date	2025-09-12
Earnings Time	bmo
EBIT	$-11.6M
EBITDA	$-11.6M
EPS	$-78.31
F Score	2
FCF	$-7.6M
FCF EV Yield	88.17x
FCF Per Share	$-11.76
Financing CF	17,549,125
Fiscal Year End	December
Founded	2,000
Income Tax	$-141,319
Investing CF	-784,657
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2025-09-12
Last Report Date	2025-12-31
Last Split Date	2026-04-06
Last Split Type	Reverse
Last10k Filing Date	2026-03-27
Ma150	15.21
Ma150ch	-72.06%
Ma20	3.64
Ma20ch	16.73%
Net CF	9,239,569
Next Earnings Date	2026-09-11
Open	4.69
Optionable	No
Position In Range	9.09
Post Close	4.25
Postmarket Change Percent	1.65
Postmarket Price	$4.32
Ppne	124,060.3
Pre Close	4.86
Price Date	2026-05-08
Ptbv Ratio	0.36
Relative Volume	0.08x
Share Based Comp	228,802
Tr6m	-84.26%
Volume	80,868

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BDRX pay a dividend?

Capital-return profile for this ticker.

Performance

BDRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BDRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+1.3%

Float: +84.9% of shares outstanding

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BDRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

55.3

Neutral momentum band

Price vs 200-day MA

-78.4%

50/200-day relationship not available

Beta (5Y)

1.16

Moves roughly with the market

Sharpe ratio

-0.77

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BDRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BDRX stock rating?

Biodexa Pharmaceuticals Plc is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BDRX analysis?

The full report lives at /stocks/BDRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BDRX?

The latest report frames BDRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BDRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.